CCR6 as a possible therapeutic target in psoriasis

Michael N. Hedrick, Anke S. Lonsdorf, Samuel T Hwang, Joshua M. Farber

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Importance of the field: Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety and convenience. Chemokine receptors are GPCRs that control leukocyte trafficking, and like other GPCRs, are good potential drug targets. The chemokine receptor CCR6 is expressed on the TH17 subset of CD4 T cells, which produces IL-17A/F, IL-22, TNF-α and other cytokines, and which has been implicated in the pathogenesis of psoriasis. CCR6 and its ligand, CCL20/MIP-3α, are highly expressed in psoriatic skin and CCR6 is necessary for the pathology induced in a mouse model of psoriasis-like inflammation. Areas covered in this review: This review summarizes the evidence for the importance of the IL-23/TH17 axis, and in particular CCR6 and CCL20 in psoriasis, dating from 2000 to the present, and discusses the possibility of inhibiting CCR6 as a treatment for the disease. What the reader will gain: The review informs the reader of the current thinking on the mechanisms of inflammation in psoriasis and the possible roles for CCR6 (and CCL20) in disease pathogenesis. Take home message: We conclude that CCR6 should be investigated as a potential therapeutic target in psoriasis.

Original languageEnglish (US)
Pages (from-to)911-922
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Volume14
Issue number9
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Psoriasis
Chemokine Receptors
Skin
Interleukin-23
T-cells
Interleukin-17
Pathology
Therapeutics
Cytokines
Ligands
Inflammation
T-Lymphocyte Subsets
Pharmaceutical Preparations
Autoimmune Diseases
Leukocytes
Chronic Disease
Safety

Keywords

  • Autoimmune disease
  • Chemokines
  • Inflammation
  • Psoriasis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

CCR6 as a possible therapeutic target in psoriasis. / Hedrick, Michael N.; Lonsdorf, Anke S.; Hwang, Samuel T; Farber, Joshua M.

In: Expert Opinion on Therapeutic Targets, Vol. 14, No. 9, 09.2010, p. 911-922.

Research output: Contribution to journalReview article

Hedrick, Michael N. ; Lonsdorf, Anke S. ; Hwang, Samuel T ; Farber, Joshua M. / CCR6 as a possible therapeutic target in psoriasis. In: Expert Opinion on Therapeutic Targets. 2010 ; Vol. 14, No. 9. pp. 911-922.
@article{399998cc994448b999b951aa161049ab,
title = "CCR6 as a possible therapeutic target in psoriasis",
abstract = "Importance of the field: Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety and convenience. Chemokine receptors are GPCRs that control leukocyte trafficking, and like other GPCRs, are good potential drug targets. The chemokine receptor CCR6 is expressed on the TH17 subset of CD4 T cells, which produces IL-17A/F, IL-22, TNF-α and other cytokines, and which has been implicated in the pathogenesis of psoriasis. CCR6 and its ligand, CCL20/MIP-3α, are highly expressed in psoriatic skin and CCR6 is necessary for the pathology induced in a mouse model of psoriasis-like inflammation. Areas covered in this review: This review summarizes the evidence for the importance of the IL-23/TH17 axis, and in particular CCR6 and CCL20 in psoriasis, dating from 2000 to the present, and discusses the possibility of inhibiting CCR6 as a treatment for the disease. What the reader will gain: The review informs the reader of the current thinking on the mechanisms of inflammation in psoriasis and the possible roles for CCR6 (and CCL20) in disease pathogenesis. Take home message: We conclude that CCR6 should be investigated as a potential therapeutic target in psoriasis.",
keywords = "Autoimmune disease, Chemokines, Inflammation, Psoriasis",
author = "Hedrick, {Michael N.} and Lonsdorf, {Anke S.} and Hwang, {Samuel T} and Farber, {Joshua M.}",
year = "2010",
month = "9",
doi = "10.1517/14728222.2010.504716",
language = "English (US)",
volume = "14",
pages = "911--922",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - CCR6 as a possible therapeutic target in psoriasis

AU - Hedrick, Michael N.

AU - Lonsdorf, Anke S.

AU - Hwang, Samuel T

AU - Farber, Joshua M.

PY - 2010/9

Y1 - 2010/9

N2 - Importance of the field: Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety and convenience. Chemokine receptors are GPCRs that control leukocyte trafficking, and like other GPCRs, are good potential drug targets. The chemokine receptor CCR6 is expressed on the TH17 subset of CD4 T cells, which produces IL-17A/F, IL-22, TNF-α and other cytokines, and which has been implicated in the pathogenesis of psoriasis. CCR6 and its ligand, CCL20/MIP-3α, are highly expressed in psoriatic skin and CCR6 is necessary for the pathology induced in a mouse model of psoriasis-like inflammation. Areas covered in this review: This review summarizes the evidence for the importance of the IL-23/TH17 axis, and in particular CCR6 and CCL20 in psoriasis, dating from 2000 to the present, and discusses the possibility of inhibiting CCR6 as a treatment for the disease. What the reader will gain: The review informs the reader of the current thinking on the mechanisms of inflammation in psoriasis and the possible roles for CCR6 (and CCL20) in disease pathogenesis. Take home message: We conclude that CCR6 should be investigated as a potential therapeutic target in psoriasis.

AB - Importance of the field: Psoriasis is a common, chronic autoimmune disease of the skin. Despite a number of effective treatments, new therapies are needed with enhanced efficacy, safety and convenience. Chemokine receptors are GPCRs that control leukocyte trafficking, and like other GPCRs, are good potential drug targets. The chemokine receptor CCR6 is expressed on the TH17 subset of CD4 T cells, which produces IL-17A/F, IL-22, TNF-α and other cytokines, and which has been implicated in the pathogenesis of psoriasis. CCR6 and its ligand, CCL20/MIP-3α, are highly expressed in psoriatic skin and CCR6 is necessary for the pathology induced in a mouse model of psoriasis-like inflammation. Areas covered in this review: This review summarizes the evidence for the importance of the IL-23/TH17 axis, and in particular CCR6 and CCL20 in psoriasis, dating from 2000 to the present, and discusses the possibility of inhibiting CCR6 as a treatment for the disease. What the reader will gain: The review informs the reader of the current thinking on the mechanisms of inflammation in psoriasis and the possible roles for CCR6 (and CCL20) in disease pathogenesis. Take home message: We conclude that CCR6 should be investigated as a potential therapeutic target in psoriasis.

KW - Autoimmune disease

KW - Chemokines

KW - Inflammation

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=77955436939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955436939&partnerID=8YFLogxK

U2 - 10.1517/14728222.2010.504716

DO - 10.1517/14728222.2010.504716

M3 - Review article

C2 - 20629596

AN - SCOPUS:77955436939

VL - 14

SP - 911

EP - 922

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 9

ER -